Changchun Hi-Tech announced that its subsidiary Shanghai Saizeng Medical Technology Co., Ltd. and Yarrow Bioscience, Inc. signed an exclusive license agreement for the GenSci098 injection project. According to the agreement, Saizeng Healthcare is expected to receive a down payment of US$120 million and recent development milestones, and will be eligible for milestone payments relating to specific R&D, regulation and commercialization. Saizeng Medical will be entitled to receive a milestone payment of up to US$1,365 million for this exclusive license, and will also be entitled to a sales commission of more than 10% of net sales after subsequent products are launched.

Changchun Hi-Tech announced that its subsidiary Shanghai Saizeng Medical Technology Co., Ltd. and Yarrow Bioscience, Inc. signed an exclusive license agreement for the GenSci098 injection project. According to the agreement, Saizeng Healthcare is expected to receive a down payment of US$120 million and recent development milestones, and will be eligible for milestone payments relating to specific R&D, regulation and commercialization. Saizeng Medical will be entitled to receive a milestone payment of up to US$1,365 million for this exclusive license, and will also be entitled to a sales commission of more than 10% of net sales after subsequent products are launched.